Morgan Stanley
ENTX icon

Morgan Stanley’s Entera Bio ENTX Stock Holding History

Morgan Stanley’s Portfolio ENTX Stock Details ENTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$885 Buy
500
+100
+25% +$125 ﹤0.01% 7529
2026
Q1 		$444 Buy
+400
New +$561 ﹤0.01% 7632
2024
Q1 		– Sell
-1,000
Closed -$600 – 7865
2023
Q4 		$600 Hold
1,000
– – ﹤0.01% 7186
2023
Q3 		$725 Sell
1,000
-100
-9% -$74 ﹤0.01% 7271
2023
Q2 		$928 Buy
1,100
+100
+10% +$85 ﹤0.01% 7306
2023
Q1 		$1.16K Hold
1,000
– – ﹤0.01% 7330
2022
Q4 		$730 Sell
1,000
-35,166
-97% -$25.5K ﹤0.01% 7518
2022
Q3 		$38K Buy
36,166
+33,400
+1,208% +$50.4K ﹤0.01% 6529
2022
Q2 		$4K Sell
2,766
-2,190
-44% -$4.87K ﹤0.01% 7444
2022
Q1 		$14K Sell
4,956
-1,012
-17% -$2.43K ﹤0.01% 7280
2021
Q4 		$17K Buy
5,968
+590
+11% +$2.21K ﹤0.01% 7274
2021
Q3 		$25K Buy
5,378
+3,188
+146% +$16.3K ﹤0.01% 7011
2021
Q2 		$13K Buy
+2,190
New +$8.1K ﹤0.01% 7151

Other funds holding ENTX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $606M AUM
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Morgan Stanley's ENTX Position: Q2 2026 in Review

Morgan Stanley increased its Entera Bio (ENTX) stake by 25% in Q2 2026, buying an estimated $125 and bringing the position to 500 shares worth $885. The position accounts for ﹤0.01% of the portfolio, ranked #7529.

Morgan Stanley first reported a position in ENTX in Q2 2021 and has held it in 13 quarters since. The position peaked at $38K in Q3 2022. 27 funds tracked by Wall St. Rank hold ENTX as of Q2 2026.

  • Morgan Stanley held 500 shares of Entera Bio worth $885 as of Q2 2026.
  • Morgan Stanley bought 100 Entera Bio shares in Q2 2026, an estimated $125.
  • Entera Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7529 holding.
  • Morgan Stanley first reported a position in Entera Bio in Q2 2021 and has held it in 13 quarters since.
  • Morgan Stanley's Entera Bio position peaked at $38K in Q3 2022.
  • 27 funds tracked by Wall St. Rank held Entera Bio as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.